These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 15860268)

  • 1. Growth factor signalling networks in breast cancer and resistance to endocrine agents: new therapeutic strategies.
    Nicholson RI; Hutcheson IR; Britton D; Knowlden JM; Jones HE; Harper ME; Hiscox SE; Barrow D; Gee JM
    J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):257-62. PubMed ID: 15860268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response.
    Schiff R; Massarweh S; Shou J; Osborne CK
    Clin Cancer Res; 2003 Jan; 9(1 Pt 2):447S-54S. PubMed ID: 12538499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The NFkappaB pathway and endocrine-resistant breast cancer.
    Zhou Y; Eppenberger-Castori S; Eppenberger U; Benz CC
    Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S37-46. PubMed ID: 16113098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalk.
    Massarweh S; Schiff R
    Endocr Relat Cancer; 2006 Dec; 13 Suppl 1():S15-24. PubMed ID: 17259554
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Growth factor-driven mechanisms associated with resistance to estrogen deprivation in breast cancer: new opportunities for therapy.
    Nicholson RI; Staka C; Boyns F; Hutcheson IR; Gee JM
    Endocr Relat Cancer; 2004 Dec; 11(4):623-41. PubMed ID: 15613443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acquired resistance to oestrogen deprivation: role for growth factor signalling kinases/oestrogen receptor cross-talk revealed in new MCF-7X model.
    Staka CM; Nicholson RI; Gee JM
    Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S85-97. PubMed ID: 16113102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unraveling the mechanisms of endocrine resistance in breast cancer: new therapeutic opportunities.
    Massarweh S; Schiff R
    Clin Cancer Res; 2007 Apr; 13(7):1950-4. PubMed ID: 17404074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Growth factor signalling and resistance to selective oestrogen receptor modulators and pure anti-oestrogens: the use of anti-growth factor therapies to treat or delay endocrine resistance in breast cancer.
    Nicholson RI; Hutcheson IR; Hiscox SE; Knowlden JM; Giles M; Barrow D; Gee JM
    Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S29-36. PubMed ID: 16113097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel mechanisms of resistance to endocrine therapy: genomic and nongenomic considerations.
    Gururaj AE; Rayala SK; Vadlamudi RK; Kumar R
    Clin Cancer Res; 2006 Feb; 12(3 Pt 2):1001s-1007s. PubMed ID: 16467116
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Hormone resistance and its modulation in breast cancer].
    Kahán Z; Thurzó L
    Orv Hetil; 2005 Apr; 146(16):731-7. PubMed ID: 15889669
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tamoxifen-induced ER-alpha-SRC-3 interaction in HER2 positive human breast cancer; a possible mechanism for ER isoform specific recurrence.
    Mc Ilroy M; Fleming FJ; Buggy Y; Hill AD; Young LS
    Endocr Relat Cancer; 2006 Dec; 13(4):1135-45. PubMed ID: 17158759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Src as a therapeutic target in anti-hormone/anti-growth factor-resistant breast cancer.
    Hiscox S; Morgan L; Green T; Nicholson RI
    Endocr Relat Cancer; 2006 Dec; 13 Suppl 1():S53-9. PubMed ID: 17259559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New approaches to reverse resistance to hormonal therapy in human breast cancer.
    Weinberg OK; Marquez-Garban DC; Pietras RJ
    Drug Resist Updat; 2005 Aug; 8(4):219-33. PubMed ID: 16054421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Membrane-initiated steroid signaling action of estrogen and breast cancer.
    Song RX
    Semin Reprod Med; 2007 May; 25(3):187-97. PubMed ID: 17447208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overcoming endocrine resistance in breast cancer: are signal transduction inhibitors the answer?
    Bedard PL; Freedman OC; Howell A; Clemons M
    Breast Cancer Res Treat; 2008 Apr; 108(3):307-17. PubMed ID: 18351454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators.
    Schiff R; Massarweh SA; Shou J; Bharwani L; Arpino G; Rimawi M; Osborne CK
    Cancer Chemother Pharmacol; 2005 Nov; 56 Suppl 1():10-20. PubMed ID: 16273359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonendocrine pathways and endocrine resistance: observations with antiestrogens and signal transduction inhibitors in combination.
    Nicholson RI; Hutcheson IR; Knowlden JM; Jones HE; Harper ME; Jordan N; Hiscox SE; Barrow D; Gee JM
    Clin Cancer Res; 2004 Jan; 10(1 Pt 2):346S-54S. PubMed ID: 14734490
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estrogen receptor: current understanding of its activation and modulation.
    Osborne CK; Schiff R; Fuqua SA; Shou J
    Clin Cancer Res; 2001 Dec; 7(12 Suppl):4338s-4342s; discussion 4411s-4412s. PubMed ID: 11916222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo models for endocrine-dependent breast carcinomas: special considerations of clinical relevance.
    Fichtner I; Becker M; Zeisig R; Sommer A
    Eur J Cancer; 2004 Apr; 40(6):845-51. PubMed ID: 15120040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy.
    Cui X; Schiff R; Arpino G; Osborne CK; Lee AV
    J Clin Oncol; 2005 Oct; 23(30):7721-35. PubMed ID: 16234531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.